Journal of Clinical Endocrinology & Metabolism, Vol 81, 199-208, Copyright © 1996 by Endocrine Society

ARTICLES

Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1- 34) in humans

M Everhart-Caye, SE Inzucchi, J Guinness-Henry, MA Mitnick and AF Stewart
Division of Endocrinology, Veterans Administration Medical Center, West Haven, Connecticut 06516, USA.

Humoral hypercalcemia of malignancy (HHM) results from the production of PTH-related protein (PTHrP) by human tumors. One previous study has reported the results of human (h) PTHrP(1-34) infusion into humans. In that report, hPTHrP(1-34) was found to be qualitatively similar to but 3- to 10-fold less potent than hPTH(1-34). Because hPTHrP(1-36) and not hPTH(1-34) is likely to be the actual amino-terminal secretory form of PTHrP, and because this previously reported lack of potency was unexpected, we repeated these studies using hPTHrP(1-36) and compared the results with those obtained with hPTH(1-34). Healthy subjects (n = 30) were infused over 6 h with either vehicle alone, hPTH(1-34) at a dose of 8 pmol/kg.h, or hPTHrP(1-36) at doses of 8 or 80 pmol/kg.h. Both hPTH(1-34) and hPTHrP(1-36) caused an increase in serum ionized calcium, a decrease in serum phosphorus, an increase in the fractional excretion of phosphorus, a decrease in the tubular maximum for phosphorus, an increase in nephrogenous cAMP excretion, and suppression of endogenous PTH(1-84). Unlike events observed in HHM, hPTHrP(1-36) induced an increase in plasma 1,25-dihydroxyvitamin D2. In addition, fractional excretion of calcium was reduced by both hPTH(1-34) and hPTHrP(1-36). In their actions on serum calcium, renal calcium and phosphorus handling, and nephrogenous cAMP excretion, hPTHrP(1-36) and hPTH(1-34) appeared equivalent in potency. These studies indicate that short-term infusion of hPTHrP(1-36) into humans reproduces most but not all of the features of HHM. In contrast to the reported findings with hPTHrP(1-34), we found the potency of hPTHrP(1-36) to be comparable with that of hPTH(1-34) in vivo in humans. In addition, unlike the situation in HHM, hPTHrP(1-36) produces an increment in plasma 1,25- dihydroxyvitamin D2. Finally, hPTHrP(1-36) has been shown for the first time to have anticalciuric effects in humans. This would suggest that, in addition to osteoclastic bone resorption, tubular reabsorbtion of calcium by hPTHrP may contribute to the hypercalcemia in patients with HHM.

This article has been cited by other articles:

				G. S Bevelander, E. S L C Pinto, A. V M Canario, T. Spanings, and G. Flik CYP27A1 expression in gilthead sea bream (Sparus auratus, L.): effects of calcitriol and parathyroid hormone-related protein J. Endocrinol., March 1, 2008; 196(3): 625 - 635. [Abstract] [Full Text] [PDF]

				J.-h. Wang, M. Pazianas, W. D. Fraser, F. Harris, and J. B. Eastwood Acute renal failure and hypercalcaemia in a man from Guyana: what is the link? Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1505 - 1508. [Full Text] [PDF]

				Y. Gao and J. U. Raj Parathyroid hormone-related protein-mediated responses in pulmonary arteries and veins of newborn lambs Am J Physiol Lung Cell Mol Physiol, July 1, 2005; 289(1): L60 - L66. [Abstract] [Full Text] [PDF]

				W. T. Noonan, J. Qian, W. D. Stuart, T. L. Clemens, and J. N. Lorenz Altered Renal Hemodynamics in Mice Overexpressing the Parathyroid Hormone (PTH)/PTH-Related Peptide Type 1 Receptor in Smooth Muscle Endocrinology, November 1, 2003; 144(11): 4931 - 4938. [Abstract] [Full Text] [PDF]

				M. J. Horwitz, M. B. Tedesco, S. M. Sereika, B. W. Hollis, A. Garcia-Ocana, and A. F. Stewart Direct Comparison of Sustained Infusion of Human Parathyroid Hormone-Related Protein-(1-36) [hPTHrP-(1-36)] Versus hPTH-(1-34) on Serum Calcium, Plasma 1,25-Dihydroxyvitamin D Concentrations, and Fractional Calcium Excretion in Healthy Human Volunteers J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1603 - 1609. [Abstract] [Full Text] [PDF]

				M. J. Horwitz, M. B. Tedesco, C. Gundberg, A. Garcia-Ocana, and A. F. Stewart Short-Term, High-Dose Parathyroid Hormone-Related Protein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 569 - 575. [Abstract] [Full Text] [PDF]

				M. A. Syed, M. J. Horwitz, M. B. Tedesco, A. Garcia-Ocaña, S. R. Wisniewski, and A. F. Stewart Parathyroid Hormone-Related Protein-(1-36) Stimulates Renal Tubular Calcium Reabsorption in Normal Human Volunteers: Implications for the Pathogenesis of Humoral Hypercalcemia of Malignancy J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1525 - 1531. [Abstract] [Full Text]

				M. Mannstadt, H. Juppner, and T. J. Gardella Receptors for PTH and PTHrP: their biological importance and functional properties Am J Physiol Renal Physiol, November 1, 1999; 277(5): F665 - F675. [Abstract] [Full Text] [PDF]

				H. J. Kalkwarf, B. L. Specker, and M. Ho Effects of Calcium Supplementation on Calcium Homeostasis and Bone Turnover in Lactating Women J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 464 - 470. [Abstract] [Full Text]

				G. W. Maier, M. E. Kreis, W. Renn, P. L. Pereira, H. U. Häring, and H. D. Becker Parathyroid Hormone after Adenectomy for Primary Hyperparathyroidism. A Study of Peptide Hormone Elimination Kinetics in Humans J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3852 - 3856. [Abstract] [Full Text]

				H. Plotkin, C. Gundberg, M. Mitnick, and A. F. Stewart Dissociation of Bone Formation from Resorption during 2-Week Treatment with Human Parathyroid Hormone-Related Peptide-(1-36) in Humans: Potential as an Anabolic Therapy for Osteoporosis J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2786 - 2791. [Abstract] [Full Text]

				T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]

				M. Wolzt, L. Schmetterer, G. Dorner, G. Zelger, J. Entlicher, S. Kapiotis, and H.-G. Eichler Hemodynamic Effects of Parathyroid Hormone-Related Peptide-(1-34) in Humans J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2548 - 2551. [Abstract] [Full Text] [PDF]

				J. G. Henry, M. Mitnick, P. R. Dann, and A. F. Stewart Parathyroid Hormone-Related Protein-(1-36) Is Biologically Active When Administered Subcutaneously to Humans J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 900 - 906. [Abstract] [Full Text] [PDF]

				T. L. Wu, R. C. Vasavada, K. Yang, T. Massfelder, M. Ganz, S. K. Abbas, A. D. Care, and A. F. Stewart Structural and Physiologic Characterization of the Mid-region Secretory Species of Parathyroid Hormone-related Protein J. Biol. Chem., October 4, 1996; 271(40): 24371 - 24381. [Abstract] [Full Text] [PDF]

				D. Miao, X.-K. Tong, G. K. Chan, D. Panda, P. S. McPherson, and D. Goltzman Parathyroid Hormone-related Peptide Stimulates Osteogenic Cell Proliferation through Protein Kinase C Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway J. Biol. Chem., August 17, 2001; 276(34): 32204 - 32213. [Abstract] [Full Text] [PDF]